Research map: Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score‐Matched Real‐World Analysis

Back to the article

Papers in this map

  1. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma · Michael Wang · 2013 · 1710 citations · Cited by this paper
  2. Association of the Affordable Care Act With Receipt of Guideline‐Concordant Adjuvant Chemotherapy for Colon and Non‐Small Cell Lung Cancer · 2026 · Related
  3. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial · John C. Byrd · 2021 · 673 citations · Cited by this paper
  4. Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification · 2026 · Related
  5. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia · Jennifer R. Brown · 2022 · 492 citations · Cited by this paper
  6. The Impact of the G8 Score on Survival Outcomes in Patients With Head and Neck Cancer Undergoing Concurrent Radiotherapy With Cetuximab due to Contraindications With Cisplatin · 2026 · Related
  7. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study · Yuqin Song · 2022 · 182 citations · Cited by this paper
  8. The Zuo Jin Wan Formula Reverses Cisplatin Resistance in Gastric Cancer by Inhibiting the Mitochondrial Translocation of Dynamin‐Related Protein 1 and Its Mediated Mitochondrial Fission and Mitophagy · 2026 · Related
  9. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial · John Francis Seymour · 2023 · 140 citations · Cited by this paper
  10. Notch3/4 Knockdown Inhibits Colon Adenocarcinoma Progression by Suppressing Tumor Cell Activity and Orchestrating VEGFA ‐Dependent Tumor Immune Microenvironment · 2026 · Related
  11. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia · Cooper Quartermaine · 2023 · 128 citations · Cited by this paper
  12. Overcoming Radiation Resistance: Ferroptosis Induction to Sensitize Solid Tumors to Radiation Therapy · 2026 · Related
  13. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE · Jennifer R. Brown · 2024 · 71 citations · Cited by this paper
  14. Inhibition of the Metalloproteinase ADAMTS5 Suppresses Colorectal Cancer Metastasis via the PEDF /Wnt/β‐Catenin Pathway · 2026 · Related
  15. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 · Andrew David Zelenetz · 2025 · 21 citations · Cited by this paper
  16. Machine Learning for Prediction of High‐Risk Infections in Patients With Cancer · 2026 · Related
  17. BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL · Kensuke Kojima · 2025 · 7 citations · Cited by this paper
  18. Watch and Wait Strategy for Locally Advanced Rectal Cancer: Update From Results of Recent Clinical Trials · 2026 · Related
  19. Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? · Santino Caserta · 2025 · 6 citations · Cited by this paper
  20. Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma · Tycel Jovelle Phillips · 2025 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)